Kazia Therapeutics Valore dell'impresa
Cos'è Valore dell'impresa di Kazia Therapeutics?
Valore dell'impresa di Kazia Therapeutics Limited è $3.91M
Qual è la definizione di Valore dell'impresa?
Il valore dell'impresa è una misura del valore di mercato totale di un'azienda. È calcolato come capitalizzazione di mercato con debito, interessi di minoranza e azioni privilegiate al netto delle disponibilità liquide e mezzi equivalenti.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Valore dell'impresa di aziende nel Health Care settore su ASX rispetto a Kazia Therapeutics
Cosa fa Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Aziende con valore dell'impresa simili a Kazia Therapeutics
- Neovasc ha Valore dell'impresa di $3.90M
- Lypsa Gems & Jewellery ha Valore dell'impresa di $3.90M
- Personas Social ha Valore dell'impresa di $3.90M
- Taura Gold Inc ha Valore dell'impresa di $3.90M
- Honey Badger Exploration ha Valore dell'impresa di $3.90M
- Golden Minerals Co ha Valore dell'impresa di $3.91M
- Kazia Therapeutics ha Valore dell'impresa di $3.91M
- Magnolia Colombia ha Valore dell'impresa di $3.91M
- Highway 50 Gold ha Valore dell'impresa di $3.91M
- Cellmid ha Valore dell'impresa di $3.92M
- Pancontinental Resources ha Valore dell'impresa di $3.92M
- ParcelPal Technology ha Valore dell'impresa di $3.92M
- Onelife Capital Advisors ha Valore dell'impresa di $3.93M